Ignite Creation Date:
2024-05-05 @ 4:40 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00291915
Status:
UNKNOWN
Last Update Posted:
2006-02-15
First Post:
2006-02-14
Brief Title:
Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis
Sponsor:
Goupe dEtudes et de Recherche Clinique En Rhumatologie
Organization:
Goupe dEtudes et de Recherche Clinique En Rhumatologie
Study Overview
Official Title:
Methotrexate Alone Versus Methotrexate in Combination With Adalimumab in Early Arthritis
Status:
UNKNOWN
Status Verified Date:
2006-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluation of two treatment modalities in early potentially severe early arthritis Methotrexate alone or in combination with adalimumab
Detailed Description:
Patients early less than 6 months active DAS52potentially severe Leiden score6 Study design12 months prospective randomized open Study treatments Methotrexate at a weekly dose of 03mgkilo alone or in combination with adalimumab 40 mg every the other week Outcome measures DAS over the 12 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None